Validation of a viral and bacterial inactivation step during the extraction and purification process of porcine collagen

Bio-Medical Materials and Engineering

Volumn 17, Issue 4, 2007, Pages 199-208

  Forest, P ^a   Morfin, F ^a   Bergeron, E ^a   Dore, J ^a   Bensa, S ^a   Wittmann, C ^a   Picot, S ^a   Renaud, F N R ^a   Freney, J ^a   Gagnieu, C ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b Laboratoire des Biomatériaux Dispositifs Médicaux et Remodelages Matriciels   (France)

Author keywords

Bacteria; Collagen; Inactivation; Porcine parvovirus; Sodium hydroxide

Indexed keywords

BACTERIA; BIOMATERIALS; COLLAGEN; EXTRACTION; PURIFICATION; VIRUSES;

INACTIVATION; PORCINE PARVOVIRUS; SODIUM HYDROXIDE;

BIOMEDICAL ENGINEERING;

COLLAGEN; COLLAGEN TYPE 1;

ANTIBIOTIC RESISTANCE; ARTICLE; ASPERGILLUS NIGER; BACILLUS CEREUS; BACTERIAL SPORE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CANDIDA ALBICANS; INOCULATION; NONHUMAN; PARVOVIRUS; PHASE SEPARATION; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN PURIFICATION; PSEUDOMONAS AERUGINOSA; SEPARATION TECHNIQUE; STAPHYLOCOCCUS AUREUS; SUSPENSION CELL CULTURE; SWINE; VIRUS INACTIVATION;

ANIMALS; BACTERIA; CELL SURVIVAL; CHEMICAL FRACTIONATION; COLLAGEN; DISINFECTANTS; DRUG CONTAMINATION; SODIUM HYDROXIDE; STERILIZATION; SWINE; VIRUS INACTIVATION; VIRUSES;

ANIMALIA; BACILLUS CEREUS; BACTERIA (MICROORGANISMS); PORCINE PARVOVIRUS; STAPHYLOCOCCUS AUREUS; SUS;

EID: 34347337748     PISSN: 09592989     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. AFNOR, NF EN 12442-3 Tissus animaux et leurs dérivés utilisés dans la fabrication des dispositifs médicaux - Partie 3 : validation de l'élimination et/ou de l'inactivation des virus et autres agents transmissibles (2000).
2. AFNOR, T72-140. Antiseptiques et désinfectants. Conservation et contrôle des souches bactériennes utilisées pour la détermination de l'activité bactéricide, 1988.
3. AFNOR, NF EN 1275. Antiseptiques et désinfectants chimiques. Essai quantitatif de suspension pour l'évaluation de l'activité bactéricide des antiseptiques et des désinfectants utilisés dans le domaine de l'agro-alimentaire, dans l'industrie, dans les domaines domestiques et en collectivité. Méthode d'essai et prescriptions (Phase 2, Etape 1), 1997.
4. AFNOR, NF EN 1040 Antispetiques et desinfectants chimiques. Activité bactéricide de bas. Méthode d'essai et prescriptions (Phase 1), 1997.
5. AFNOR, NF T72-231 Antiseptiques et désinfectants utilisés à l'état liquide, miscibles à l'eau - Détermination de l'activité sporicide - Méthode par filtration sur membranes, 1988.
6. R.W. Amareld, Jr., M. Wersocki, M. Drohan, W.N. Drohan, W.H. Burgess, D.M. Mann and R.Y. Forng, Controlled gamma-irradiation mediated pathogen inactivation of human urokinase preparations with significant recovery of enzymatic activity, Biologicals 31(4) (2003), 261-264.
7. K. Berns, Parvoviridae: The viruses and their replication, in: Virology, K.D. Fields, BN and Howley PM, eds, Philadelphia, Lippincott-Raven Publishers, 1996, p. 2174.
8. J. Blumel, I. Schmidt, H. Willkommen and J. Lower, Inactivation of parvovirus B19 during pasteurization of human serum albumin, Transfusion 42(8) (2002), 1011-1018.
9. S. Borovec, C. Broumis, W. Adcock, R. Fang and E. Uren, Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat, Biologicals 26(3) (1998), 237-244.
10. N. Boschetti, K. Wyss, A. Mischler, T. Hostettler and C. Kempf, Stability of minute virus of mice against temperature and sodium hydroxide, Biologicals 31(3) (2003), 181-185.
11. S. Chin, R. Jin, X.L. Wang, J. Hamman, G. Marx, X. Mou, I. Andersson, L.O. Lindquist and B. Horowitz, Virucidal treatment of blood protein products with UVC radiation, Photochem. Photobiol. 65(3) (1997), 432-435.
12. D.D. Circulaire, No 100 relative aux précautions à observer en milieu chirurgical et anatomophatologique face aux risques de transmission de la maladie de Creutzfeld Jacob, 11 décembre 1995.
13. CPMP/BWP/268/95, Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses Version 2. February 1996 (CPMP/ICH/294/95), Consensus guideline, 16 July 1997 and (CPMP/BWP/269/95) Rev 3, January 2001. Date for coming into operation 14 August 1996 (February 1996).
14. D. Dormont, [Nature and physicochemical and biological properties of non conventional transmissible agents or prions: consequences for public health], Pathol. Biol. (Paris) 43(2) (1995), 124-136.
15. J. Hodde and M. Hiles, Virus safety of a porcine-derived medical device: evaluation of a viral inactivation method, Biotechnol. Bioeng. 79(2) (2002), 211-216.
16. C.H. Lee, A. Singla and Y. Lee, Biomedical applications of collagen, Int. J. Pharm. 221(1-2) (2001), 1-22.
17. H. Mahnel, Variations in resistance of viruses from different groups to chemico-physical decontamination methods, Infection 7(5) (1979), 240-246.
18. W.R. McLaughlin, K.B. Hallberg and O.H. Tuovinen, Chemical inactivation of microorganisms on rigid gas permeable contact lenses, Optom. Vis. Sci. 68(9) (1991), 721-727.
19. W. Mengeling, Porcine parvovirus properties and prevalence of a strain isolated in the United States, Am. J. Vet. Res. 33(11) (1972), 2239-2248.
20. S.I. Miekka, R.Y. Forng, R.G. Rohwer, C. MacAuley, R.E. Stafford, S.L. Flack, M. MacPhee, R.S. Kent and W.N. Drohan, Inactivation of viral and prion pathogens by gamma-irradiation under conditions that maintain the integrity of human albumin, Vox Sang. 84(1) (2003), 36-44.
21. J.A. Ramshaw, J.A. Werkmeister and V. Glattauer, Collagen-based biomaterials, Biotechnol. Genet. Eng. Rev. 13 (1996), 335-382.
22. L. Reed and H. Muench, A simple method of estimating fifty per cent end points, Am. J. Hyg. 27 (1938), 493-497.
23. C.F. Rousseau and C.H. Gagnieu, In vitro cytocompatibility of porcine type I atelocollagen crosslinked by oxidized glycogen, Biomaterials 23(6) (2002), 1503-1510.
24. P.H. Ruane, R. Edrich, D. Gampp, S.D. Keil, R.L. Leonard and R.P. Goodrich, Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light, Transfusion 44(6) (2004), 877-885.
25. S.A. Sattar and V.S. Springthorpe, Survival and disinfectant inactivation of the human immunodeficiency virus: a critical review, Rev. Infect. Dis. 13(3) (1991), 430-447.
26. A.A. Simpson, B. Hebert, G.M. Sullivan, C.R. Parrish, Z. Zadori, P. Tijssen and M.G. Rossmann, The structure of porcine parvovirus: comparison with related viruses, J. Mol. Biol. 315(5) (2002), 1189-1198.
27. N.M. Troccoli, J. McIver, A. Losikoff and J. Poiley, Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration, Biologicals 26(4) (1998), 321-329.
28. R.W. Van Holten, D. Ciavarella, G. Oulundsen, F. Harmon and S. Riester, Incorporation of an additional viral-clearance step into a human immunoglobulin manufacturing process, Vox Sang. 83(3) (2002), 227-233.
29. W. Weichert, J. Parker, A. Wahid, S. Chang, E. Meier and C. Parrish, Assaying for structural variation in the parvovirus capsid and its role in infection, Virology 250 (1998), 106-117.